Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Medtronic
Cipla
AstraZeneca
Dow
Boehringer Ingelheim
Covington
Accenture
US Department of Justice
Julphar

Generated: October 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,572,935

« Back to Dashboard

Which drugs does patent 7,572,935 protect, and when does it expire?


Patent 7,572,935 protects APLENZIN and is included in one NDA. There have been three Paragraph IV challenges on Aplenzin.

This patent has forty-nine patent family members in seventeen countries.

Summary for Patent: 7,572,935

Title:Modified release formulations of a bupropion salt
Abstract:The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Inventor(s): Oberegger; Werner (Mississauga, CA), Maes; Paul (Toronto, CA), Turchetta; Stefano (Rome, IT), Massardo; Pietro (Rome, IT), Saleh; Mohammad Ashty (Oakville, CA)
Assignee: Biovail Laboratories International S.R.L. (St. Michael, BB)
Application Number:11/762,840
Patent Claim Types:
see list of patent claims
Composition; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Valeant Pharms North
APLENZIN
bupropion hydrobromide
TABLET, EXTENDED RELEASE;ORAL022108-001Apr 23, 2008RXYesNo► Subscribe► SubscribeY
Valeant Pharms North
APLENZIN
bupropion hydrobromide
TABLET, EXTENDED RELEASE;ORAL022108-002Apr 23, 2008RXYesNo► Subscribe► SubscribeY
Valeant Pharms North
APLENZIN
bupropion hydrobromide
TABLET, EXTENDED RELEASE;ORAL022108-003Apr 23, 2008RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,572,935

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,569,611Modified release formulations of a bupropion salt► Subscribe
8,932,628Modified release formulations of a bupropion salt► Subscribe
7,884,136Modified-release formulations of a bupropion salt► Subscribe
7,241,805Modified release formulations of a bupropion salt► Subscribe
7,645,802Bupropion hydrobromide and therapeutic applications► Subscribe
8,354,453Bupropion hydrobromide and therapeutic applications► Subscribe
7,645,901Modified release formulations of a bupropion salt► Subscribe
7,563,823Modified release formulations of a bupropion salt► Subscribe
9,504,640Modified release formulations of a bupropion salt► Subscribe
7,671,094Bupropion hydrobromide and therapeutic applications► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,572,935

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2011500865► Subscribe
Colombia6270385► Subscribe
Costa Rica9609► Subscribe
Costa Rica11259► Subscribe
EcuadorSP077999► Subscribe
EcuadorSP109923► Subscribe
European Patent Office1896002► Subscribe
European Patent Office2032124► Subscribe
European Patent Office2185139► Subscribe
South Korea20100077182► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Merck
Boehringer Ingelheim
McKinsey
Teva
Citi
Moodys
Daiichi Sankyo
Chubb
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot